Centralized Controller for Epilepsy Medication Authorization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems for managing epilepsy medication distribution are inadequate, particularly for severe subtypes like Dravet Syndrome, as they lack centralized control and are prone to misdiagnosis, errors in prescription transcription, and delays, which can be disastrous for patients.
Innovation Solution
A centralized system with a controller that authorizes medication prescriptions based on genetic test results, schedules subsequent tests, and controls the format of test data, ensuring only authorized medical professionals can prescribe, and uses a database to monitor patient compliance and adjust prescriptions accordingly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a decentralized system is used for medication distribution, then ease of operation is improved, but reliability deteriorates due to misdiagnosis, transcription errors, and delays
Solution Approach 1:
The patent introduces a centralized control system that acts as an intermediary between medical practitioners and patients. This central controller receives diagnostic data, verifies it against established criteria, and authorizes medication prescriptions. The intermediary ensures reliability by centralizing control and validation, preventing errors that occur in decentralized systems while maintaining operational ease through automated processes.
Solution Approach 2:
The system implements continuous feedback loops where the central controller monitors patient data, prescription compliance, and treatment outcomes. This feedback mechanism allows the system to verify diagnoses, track medication effectiveness, and adjust treatments accordingly, thereby improving reliability through ongoing validation and correction of medical decisions.
2Device complexity
If manual prescription processes are used, then device complexity is reduced, but loss of time increases due to delays in medication delivery
Solution Approach 1:
The patent replaces manual mechanical processes with an automated electronic system. The central controller electronically receives diagnostic data, automatically verifies it against programmed criteria, and electronically authorizes prescriptions. This substitution of manual processes with automated electronic control significantly reduces the time required for medication delivery while the standardized algorithms keep system complexity manageable.
Solution Approach 2:
The system performs preliminary actions by pre-programming diagnostic criteria, verification rules, and prescription protocols in the central controller. When diagnostic data is received, the system has already established the framework for rapid verification and authorization, eliminating the need for time-consuming manual review processes while maintaining appropriate complexity through pre-established rules.
3Measurement precision
If standardized test formats are enforced, then measurement precision is improved, but adaptability deteriorates
Solution Approach 1:
The patent employs parameter changes by allowing the central controller to adjust verification criteria and test requirements based on patient-specific factors. While maintaining standardized formats for data collection and analysis to ensure precision, the system can modify which tests are required, what thresholds apply, and how results are interpreted based on individual patient characteristics, genetic profiles, and clinical presentations, thereby preserving adaptability.
Data Source
AI summary
A system of controlling distribution of a medication in the treatment or prevention of epilepsy is provided. A central controller of the system has a data store and one or more processors for reading and writing data to the data store. The data store comprises a database of patient records, each patient record having a medication authorization field. The central controller can output an authorization of a first prescription of epilepsy medication to a patient in dependence upon genetic test results for the patient and schedules a subsequent test for the patient prior to authorization of a subsequent prescription of epilepsy medication. Also provided are methods in which the subject systems find use. The systems and methods find use in the treatment of severe subtypes of epilepsy or refractory epilepsy, such as Dravet Syndrome.